Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG

Queen Saovabha Memorial Institute210 enrolled

Overview

A comparative,randomized (1:1)study to evaluate the safety and immunogenicity of a new chromatographically purified vero cell rabies vaccine (SPEEDA) and chromatographically purified vero cell rabies vaccine (SPEEDA)which is filled by Queen Saovabha Memorial Institute (TRCS SPEEDA)vs. reference vaccine (purified vero cell vaccine; VERORAB)when using with post-exposure rabies intradermal vaccination with or without equine rabies immunoglobulin.

Rabies is an important world health problem especially in developing countries.Although the case-fatality ratio of human rabies is 100%,the disease is preventable by the modern cell-culture vaccine and rabies immunoglobulin.Post-exposure rabies vaccination with the modified Thai Red Cross intradermal(modified TRC-ID)regimen has been approved by WHO and proven to be immunogenic and effective. It represents a significant saving in vaccine cost and is now established in several developing countries. SPEEDA,chromatography purified vero cell derived rabies vaccine,approved by Thai FDA on 8 April 2009 and drug registration code of SPEEDA is 1C 90022/51. This study has a goal to determine the immunogenicity and safety of SPEEDA and TRCS-SPEEDA (SPEEDA which is filled by Queen Saovabha Memorial Institute)vs. reference vaccine (purified vero cell vaccine; VERORAB)when using with post-exposure rabies intradermal vaccination with or without equine rabies immunoglobulin.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

210

Conditions

Rabies

Interventions

SPEEDA and TRCS SPEEDABIOLOGICAL

For modified TRC-ID regimen,0.1 ml of SPEEDA, TRCS SPEEDA or VERORAB will be given at each of two sites,intradermally on upper arms on days 0,3,7 and 28. For ESSEN regimen, 1 vial of SPEEDA will be given intramuscularly at upper arm on days 0,3,7,14 and 28. For ERIG,it would be given in a single dose 40 IU/Kg at the same time as the first dose of vaccine. ERIG will be infiltrated around and into all wounds as recommended by WHO for patients in group IV and injected intramuscular at each of both gluteal areas for participants in group III,V,VI

Eligibility

Sex: ALLMin age: 15 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * subjects are healthy population older than 15 years. * subjects are willing to give signed informed consents. * subjects are willing to give blood samples on recommended days. * subjects are available for follow up according to the table of administration Exclusion Criteria: * subjects who had received any type of rabies vaccination in the past * subjects who had received rabies immunoglobulin in the past * subjects who had known as immunocompromised hosts * subjects on steroids or any other immunosuppressant * subjects on concomitant antimalarials * subjects who have received of any blood products within the previous 3 months * subjects with history of allergy to any ingredient of the vaccine * subjects who had known as pregnancy in first recruitment

Locations (2)

Suda Sibunruang

Bangkok, Thailand

Queen Saovabha Memorial Institute

Bangkok, Thailand

Outcomes

Primary Outcomes

immunogenicity (the level of rabies neutralizing antibodies by RFFIT test)

The immunogenicity (Rabies neutralizing antibodies) would be checked from the blood samples for 7 times (on days 0,7,14,28,90,180 and 360)for one year duration in each phase.

Time frame: 32 months

Secondary Outcomes

safety

This would based on general examination, local examination and subjective evaluation of both solicited and unsolicited adverse events.

Time frame: 32 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.